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Abstract
Argonaute 2 (Ago2) is the only mammalian Ago protein capable of mRNA cleavage. It has been reported that the activity of
the short interfering RNA targeting coding sequence (CDS), but not 39 untranslated region (39UTR) of an mRNA, is solely
dependent on Ago2 in vitro. These studies utilized extremely high doses of siRNAs and overexpressed Ago proteins, as well
as were directed at various highly expressed reporter transgenes. Here we report the effect of Ago2 in vivo on targeted
knockdown of several endogenous genes by siRNAs, targeting both CDS and 39UTR. We show that siRNAs targeting CDS
lose their activity in the absence of Ago2, whereas both Ago1 and Ago3 proteins contribute to residual 39UTR-targeted
siRNA-mediated knockdown observed in the absence of Ago2 in mouse liver. Our results provide mechanistic insight into
two components mediating RNAi under physiological conditions: mRNA cleavage dependent and independent. In addition
our results contribute a novel consideration for designing most efficacious siRNA molecules with the preference given to
39UTR targeting as to harness the activity of several Ago proteins.
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Introduction
RNAi and in particular siRNA technology has advanced from
bench to bedside in under a decade [1,2]. siRNA utilizes a natural
pathway that cells designed for miRNA induced gene modulation
and antiviral protection. While interactions between miRNAs and
the proteins which constitute RNA-induced silencing complex
(RISC) have been well studied [3,4], including RISC loading [5–7]
and resulting complex structure [8–10], the interactions of
exogenous siRNAs with Argonaute proteins are less well under-
stood. Functional interaction of siRNA with Ago2 has been
demonstrated by the loss of knockdown in the absence of Ago2 or
in the presence of a Slicer-incompetent Ago2, and by the
reconstitution of the Slicer activity with purified wild-type Ago2
protein [11,12]. Little is known about functionality of siRNA
binding to the other three mammalian Argonaute family
members. Some residual knockdown in the absence of Ago2 has
been reported by several groups [6,13,14], while others have not
seen response to siRNA treatment in cells lacking Ago2 [11]. All
four Ago proteins encoded in the mammalian genome are
expressed in most tissues and cultured mammalian cell lines,
although in different proportions [15]. They have all been shown
to bind miRNAs and siRNAs indiscriminately of sequence
[11,12,16,17], to interact with a common set of helicases and
mRNA-binding proteins, including the three TNRC6 proteins (2
A,2B,2C) [18,19] and to localize to P-bodies in mammalian cells,
with a capability of targeting mRNAs to the general eukaryotic
machinery for translation control and mRNA degradation [20–
22]. This is true for Ago3 and Ago4 as well, though they do not
possess either passenger strand cleavage activity or siRNA strand
dissociating activity [5].
Thus, the question remains: does a siRNA assembled in RISC
with a non-Slicer Argonaute protein within a mammalian cell pair
with mRNAs to contribute to post-transcriptional repression by
translation inhibition and/or targeting the mRNA for degrada-
tion, similar to miRNA [20,23–27]? Do the functions of Ago1,
Ago3, and Ago4 differ from those of Ago2 [27,28]? Or do these
complexes compete with Ago2-containing RISC for the target
mRNA sites and/or siRNA reducing potency of the siRNA
[13,29]? It is likely that both alternatives are true under different
conditions: (i) Excess of non-Slicer Argonautes may effectively
compete with Ago2, decreasing target mRNA knockdown, as has
been shown for shRNA [13]; (ii) in the absence of Ago2 non-Slicer
Argonautes may provide sufficient miRNA-guided knockdown to
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sustain cell viability [30], if not full ontogenesis (as germline
mutation of the Ago2 gene is embryonic lethal [11,31]); and (iii) in
some cases non-Slicer Argonautes may cause target-specific siRNA
mediated mRNA degradation [13,14,27].
Until now, the limited number of genes tested and insufficient
transcript coverage by targeting siRNAs have impeded the
understanding of the role of siRNA’s sequence and target site
position within the transcript, which led to controversial results
and hypotheses. Several groups have shown previously that some
of siRNAs retain part of their on-target activity in the absence of
Ago2 [6,13,14]. These data came from experiments with
transgenic targets and only one siRNA per target, leaving an
open question whether this effect is due to the nature of the target
or some features of siRNAs, such as sequence or position of the
target site within the mRNA.
We are the first to have systematically analyzed the effect of
Ago2 absence on knockdown of endogenous genes by siRNAs,
targeting coding sequence (CDS) and 39 untranslated region
(39UTR) of several genes, including knockdown with siRNA pairs
targeting CDS and 39UTR of three genes: coagulation factor VII
(FVII), fatty acid desaturase 1 (Fads1), and Ras-related protein
Rab-5C (Rab5c) tested in vivo. We demonstrate complete loss of
activity of the siRNAs targeting CDS regions of these three genes
in the absence of Ago2 in mouse liver. We show persistence of
knockdown by siRNAs targeting 39UTRs of the same three genes,
and that both Ago1 and Ago3 proteins present in physiological
amounts contribute to residual knockdown observed in the
absence of Ago2 in liver. Ago1 and Ago3 (and possibly Ago4 in
tissues, where it is more abundant) are involved in 39UTR-
targeted siRNA-mediated knockdown of mRNA (indicating
potential benefits of targeting 39UTR versus CDS).
Results and Discussion
siRNAs targeting CDS and 39UTR differ in their Ago2
dependence in vitro
In order to systematically analyze the role of Ago2 in the
knockdown mediated by exogenous siRNA we tested the activity
of a collection of siRNAs targeting different regions of four
endogenous gene transcripts (Fads1, Fads2, Rab5a, and Rab5c;
sequences of duplexes are listed in Table S1) in mouse embryonic
fibroblast (MEF) cells expressing the wild-type Ago2 (MEF
harboring Ago2 flanked by LoxP sites, Ago2fl/fl) or its truncated
inactive variant (Ago22/2) [31]. Indeed, significant part of siRNAs
retained silencing activity in the absence of Ago2. Mapping of
their target site positions showed that only siRNAs targeting
39UTR remained active, while all tested siRNAs targeting CDS
did not cause any knockdown in the absence of Ago2 (Fig. 1A). All
16 duplexes targeting CDS showed robust knockdown (.75%) in
Ago2fl/fl MEF cells, while showing no significant knockdown (,
20%) in Ago22/2 MEF cells. At the same time, 21 of 28 duplexes
targeting 39UTR retained activity in Ago22/2 cells, this effect was
observed even for the less potent siRNAs (which caused only
,60%–70% target knockdown in control cells). This effect
appears to be independent of the strength and sequence of
siRNA, as several different duplexes with IC50 concentration
ranging from 0.05 nM to 0.8 nM, targeting the 39UTR of the
same gene, retain partial activity. Furthermore, since the same was
seen for four targeted genes, it is evidently not a gene-specific effect
either. It was recently shown that miRNA activity is inhibited in
translated regions of transcripts and thus miRNAs preferentially
target 39UTR [32], our data suggest that in the absence of Ago2
exogenous siRNAs follow the same rules.
Next we sought to determine the maximum level of knockdown
that can be achieved in the absence of Ago2 and to verify absence
of knockdown with duplexes targeting CDS at higher concentra-
tions of siRNA. To this end we transfected Ago22/2 or Ago2fl/fl
MEF cells with increasing concentrations of siRNAs targeting
CDS or 39UTR of two genes: Fads1 and Rab5c, selected from the
set used in the first experiment, based on their high activity in the
presence of Ago2 (these duplexes are bold in Table S1). All tested
siRNAs reached saturation at 40 nM or lower in Ago2fl/fl MEF
cells (Figures 1B and C). The duplexes targeting CDS did not
demonstrate any activity in Ago22/2 MEF cells even at this
maximal dose. All of the tested duplexes targeting 39UTR showed
dose-dependent knockdown, irrespective of their relative positions
within 39UTR, reaching saturation at the highest dose tested both
in control and Ago22/2MEF cells. At the same time, the depth of
achievable knockdown in Ago22/2 MEF cells was always less
profound, than in control cells, in agreement with what was shown
previously [14]. Just as duplexes differ in their effectiveness in the
presence of Ago2, the depth of knockdown observed in Ago22/2
MEF cells also varied. It may be dependent on the efficiency of
loading and activation of particular siRNAs in RISC containing
different non-Slicer Argonaute proteins [6].
Role of Ago2 in CDS- and 39UTR-targeted knockdown
We further validated the results obtained in Ago22/2 MEFs by
transiently reducing levels of Ago2 with siRNA against Ago2. We
developed siRNA targeting the 39UTR of Ago2 transcript
allowing sustained Ago2 knockdown in wild-type cells. To confirm
the role of Ago2 in knockdown directed by siRNAs targeting CDS
or 39UTR, we utilized double-transfection strategy described by
[14,33]. We transfected Ago2fl/fl MEF cells with siRNA targeting
Ago2 mRNA, followed in 24 hours by transfection with a mixture
of siRNAs targeting CDS and 39UTR used earlier in the
experiments with knockout cells (Fig. 1D). Since MEF cells have
been shown to divide rapidly [34] and therefore dilute transfected
siRNA fast, the transfection with Fads1 and Rab5c siRNAs mixes
was combined with second siLuc (control siRNA targeting
Luciferase mRNA) or siAgo2 treatment, to ensure sustained
downregulation of Ago2 protein. In this experiment siRNA
targeting CDS of Fads1 mRNA was combined with equal amount
of siRNA targeting 39UTR of Rab5c mRNA, or siRNA targeting
39UTR of Fads1 mRNA was combined with siRNA targeting CDS
of Rab5c mRNA, to control effect of siRNAs targeting different
regions of transcripts in the same cells simultaneously. Ago2
siRNA treatment led to over 80% reduction in Ago2 mRNA and a
decrease in efficacies of all Fads1 and Rab5c siRNAs tested, with
the more pronounced effect on duplexes targeting CDS: the
knockdown of Fads1 mRNA was significantly decreased and in the
case of Rab5c mRNA the knockdown was lost. Thus, the
phenotype observed in Ago22/2 MEF cells, namely the loss of
CDS-targeted knockdown and weakening of activity of siRNA
targeting 39UTR may be attributed to the absence of Ago2. Our
results are in agreement with previous data where levels of Ago2
were downregulated using a treatment with RNase H-dependent
antisense oligonucleotides [14].
To test whether catalytic activity of Ago2 is indispensable for the
knockdown mediated by siRNA targeting CDS we introduced
wild-type Ago2 or Ago2 (D669A), which is catalytically inactive
Slicer-incompetent mutant [35] in Ago22/2 MEF cells, followed
by transfection with the same siRNA duplexes targeting CDS or
39UTR of Fads1 mRNA as used above. Only the expression of the
wild-type Ago2, but not the catalytically inactive mutant Ago2
restored CDS-targeted knockdown (Figure S1). Possible difference
in mechanisms of action of miRNA targeting CDS and 39UTR
RISC Substrate Specificity In Vivo
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Figure 1. Differential Ago2 dependence of siRNAs targeting coding sequence (CDS) and 39-untranslated region (39UTR) of mRNA
in vitro. (A) Mouse embryonic fibroblast (MEF) cells, Ago2fl/fl and Ago22/2 (wild-type and Ago2 knockout) were transfected with 10 nM of siRNAs
targeting CDS or 39UTR (16 or 28 siRNAs, respectively, Table S1) of mRNAs of four genes: Fads1, Fads2, Rab5a, and Rab5c. Levels of expression of
target-gene mRNA in Ago2fl/fl MEF cells and Ago22/2 MEF cells measured by branched DNA (bDNA) assay 24 h post-transfection were plotted as
percentage of relative target mRNA compared to Luciferase siRNA transfected controls. (B, C) Ago22/2 MEF cells (square) or Ago2fl/fl MEF cells (circle)
were transfected with siRNAs targeting CDS or 39UTR of Fads1 (B) or Rab5c (C) mRNA (relative positions of target sites within mRNA are shown).
Transfection and assay as described in A, but dilution series with the maximum dose of 40 nM were done. Combined results of two independent
transfections are shown. (D) Ago2fl/fl MEF cells were transfected with 10 nM siRNA targeting 39UTR of Ago2 (Eif2c2) mRNA or Luciferase, followed by
transfection with two combinations of siRNAs targeting Fads1 and Rab5c (CDS-targeting for one gene and 39UTR-targeting for the other gene, 10 nM
each, or 20 nM of Luciferase siRNA control) 48 hours later. Levels of target-genes and Ago2 mRNA expression measured by bDNA assay 24 h after
RISC Substrate Specificity In Vivo
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was predicted based on patterns of their conservation, suggesting
unique role of Ago2 in CDS-targeted knockdown by miRNA [36].
These data combined with our observation of complete depen-
dence of siRNA targeting CDS on Ago2 led us to hypothesize that
Ago2 has a unique role in CDS-targeted knockdown by siRNA.
Failure of the particular mutant Ago2 to rescue the Ago22/2
phenotype may indicate but does not imply Slicer enzymatic
activity of Ago2 as prerequisite for inhibition of targets with CDS
sites. D669A substitution may modify overall functionality of Ago2
in addition to Slicer activity. This merits further investigation and
can be tested by comparison of various Slicer-inactive mutants in
similar rescue experiments.
Cleavage-independent siRNA-directed mRNA
knockdown in the absence of Ago2
To establish if reduction in a transcript level in the absence of
Ago2 depended on Slicer, we performed 59RACE on total RNA
isolated from Ago2fl/fl MEF cells and Ago22/2 MEF cells
transfected with specific (Rab5c-39UTR-near) or control (Lucifer-
ase) siRNA for 3 hours. Prior to 59RACE knockdown in the RNA
samples was verified by branched DNA (bDNA) assay (Fig. 2A).
siRNA targeting the 39UTR of Rab5c caused considerable
knockdown in both control and Ago22/2 MEF cells even at such
an early time point after transfection. The knockdown level
reached by 24 hours post-transfection with siRNA targeting
39UTR was a lot deeper in both types of cells, while in Ago22/2
MEF cells transfected with siRNA targeting CDS there was no
significant mRNA knockdown even at 24 hour time point (Figure
S2A). Interestingly, knockdown seems to develop slower in the
absence of Ago2, as seen by comparison of 3 h-long and 24 h-long
treatments, supporting a miRNA-like mechanism, where transla-
tional inhibition precedes mRNA degradation [20].
PCR products of the 59RACE were visualized on agarose gel
(Fig. 2B and Fig. S2B), gel purified, cloned, and sequenced. All of
clones sequenced from the Ago2fl/fl MEF cells transfected with
specific (Rab5c-39UTR-near) siRNA mapped to the predicted
cleavage site, while none of the clones from Ago22/2 MEF cells
did (Figure S3). Instead, in several independent amplification
reactions we have detected products of variable lengths, similar to
products found in some of the control Luciferase siRNA treated
samples, which are characteristic of random mRNA breaks in the
absence of Ago2 siRNA-specific targeting, and suggest target-site
cleavage independent miRNA-like mechanism of mRNA degra-
dation (Figure S3 and data not shown). The same mechanism has
been shown for siRNA mediated Ago2- and Dicer-independent
off-target degradation of mRNA [6,14]. Interestingly, most of the
59RACE products from Ago22/2 MEF samples treated with
Rab5c-39UTR-near siRNA mapped to Rab5c mRNA, while very
few of the 59RACE products from samples treated with siRNA
targeting Luciferase mRNA mapped to Rab5c mRNA. This
indicates that there are more Rab5c mRNA degradation products,
which can be ligated to the adapter and amplified (mRNA needs
to be decapped, broken, or cleaved by an endonuclease to obtain a
phosphate-free 59end and become suitable substrate for T4 RNA
ligase) in the presence of specific siRNA, even in the absence of
Ago2 (Supplemental Figure S3 and data not shown). Thus, Ago2 is
indispensable for siRNA-mediated cleavage of mRNA, while
significant gene knockdown can be achieved by siRNA treatment
in the absence of Ago2, by other means of RISC-dependent
mRNA degradation [22,25,27].
In vivo CDS-targeted knockdown is fully dependent,
while 39UTR-targeting siRNA is partially dependent on
Ago2
Next we decided to address whether the observed difference in
dependence of siRNAs targeting CDS and 39UTR on Ago2 is
reproduced in vivo. First, we confirmed the absence of Ago2
mRNA in liver of knockout animals (Fig. 3A). The absence of
Ago2 has not led to compensatory changes in the expression of
other members of the Argonaute protein family at the mRNA level
(Fig. 3A). Similarly, we have seen unchanged levels of mRNA of
each of the remaining Argonautes in MEF cells and mice with
every single non-Slicer Ago knockout as well (Table S2). The
residual expression of the mRNA of knockout genes detected by
qRT-PCR in animals knockout for these genes shows the level of
transcription of the truncated version of a given gene, because
qPCR probes we used target exons not deleted as the result of
knockout [31]. In the case of Ago2 knockout animals mRNA and
protein signals may additionally originate from non-parenchymal
cells in the liver, as Ago2 is hepatocyte-specific knockout.
In a recent report, Forman and colleagues have suggested that
miRNA target sites in CDS and 39UTR may differ in mechanism
of action and in Argonaute proteins involved in knockdown. They
have shown differences in patterns of sequence conservation
between CDS and 39UTR miRNA target sites, including absence
of preference for looping and preference for greater number of
bound nucleotides in CDS miRNA target sites. Together with the
CDS-targeting siRNA dependence on Ago2 this led us to surmise
that Ago2 may be the only Argonaute capable of targeting CDS,
directed by either siRNA or miRNA. To test this hypothesis we
have measured relative mRNA expression levels of Dicer1– a let-7
CDS-target [36] – in the livers of Ago2fl/fl and Ago22/2 mice
(Fig. 3A). No difference was observed, furthermore, the negative
result of the rescue experiment with catalytically inactiveAgo2
(Figure S1) points at the Slicer activity as the prerequisite for CDS-
targeted knockdown by siRNA. Thus CDS-targeted miRNAs,
unlike siRNAs, do not interact exclusively with Ago2; the
difference in sequence conservation patterns of CDS and
39UTR miRNA target sites observed by Forman and colleagues
may be explained by additional conservation constrains within
CDS.
We compared CDS and 39UTR siRNA target sites for the two
genes – Fads1 and Rab5c – in vivo by treating mice with LNP
siRNA formulations (Fig. 3B, C). We show that they behave the
same as they did in vitro, and that a third gene – FVII – has the
same knockdown profile (Fig. 3D). In the Rab5c CDS/UTR
siRNA pair the CDS duplex is less effective (IC50 values are 1 nM
and 0.1 nM, respectively), so one may argue that loss of
knockdown is due to insufficient dose. In contrast, both duplexes
targeting Fads1 mRNA are highly potent, so the difference in the
efficacy of knockdown between duplexes targeting CDS and
39UTR observed in this case supports the hypothesis of direct
influence of position within the transcript. In addition, dose
responses done in vitro (Fig. 1B, C) have demonstrated the
absence of knockdown directed by the highest doses of siRNAs
targeting CDS even for the most potent ones (judging by their
activity in Ago2fl/fl MEF cells). In fact, the distribution of duplexes
in the graph on Figure 1A shows that this is true for multiple
siRNAs targeting different genes: siRNAs targeting CDS form a
tighter group than the ones targeting 39UTR, all showing robust
second transfection were plotted as percentage of relative target mRNA compared to Luciferase siRNA-transfected control (mean 6 s.d., n = 3).
Legend in the bottom left corner of the graph also indicates the line in the X-axis describing the treatment type (none, CDS, 39UTR) by target gene.
doi:10.1371/journal.pone.0101749.g001
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knockdown in Ago2fl/fl MEF cells and insignificant knockdown in
Ago22/2 MEF cells. Thus, the depth of 39UTR-targeted
knockdown in the presence of Ago2 does not predict the depth
of Ago2 independent mRNA knockdown.
In the absence of Ago2 CDS-targeted siRNA may influence the
protein level of the targeted gene without causing its mRNA
degradation, as had been shown for some miRNA, reviewed in
[4]. To test the translational repression hypothesis we have
Figure 2. Cleavage independent siRNA-mediated degradation of mRNA in the absence of Ago2. Ago2fl/fl MEF cells and Ago22/2 MEF
cells were transfected with 10 nM of siRNAs targeting Luciferase, or CDS, or 39UTR of the Rab5c mRNA. bDNA assay (A) and 59RACE (B) were
performed on total RNA isolated from cells 3 h post-transfection. (A) Data is presented as mean 6 s.d. for two technical replicates of bDNA
measurement. (B) 59RACE nested PCR detection of cleavage product. Numbers of clones bearing expected inserts are indicated below corresponding
lanes of the gel (expected PCR product length is 145 bp; expected adapter/Rab5c junction sequence is shown below; 16 clones were sequenced for
each PCR reaction).
doi:10.1371/journal.pone.0101749.g002
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Figure 3. siRNAs targeting CDS and 39UTR differ in their Ago2 dependence in vivo. Data points are levels of mRNA measured by qRT-PCR
in the livers (harvested 24 hours post-injection) of mice i.v.-injected with LNP-formulated siRNAs, as described in Materials and Methods, expressed as
a percentage of mRNA levels in control siRNA-treated animals. (A) mRNA expression of Argonautes and Dicer1 in Ago2fl/fl and Ago22/2 mouse liver
(mean 6 s.d., n = 4). (B) Levels of Fads1 mRNA in livers of Ago22/2 mice and Ago2fl/fl mice (mean 6 s.d., n = 2–3) treated with siRNAs targeting Fads1
CDS or 39UTR at 0.5 mg/kg. (C) Rab5c mRNA levels after treatment with siRNAs targeting its CDS or 39UTR-far at 1 mg/kg (mean 6 s.d., n = 2–3). (D)
FVII mRNA in the liver of animals treated with siRNAs (mean 6 s.d., n = 4–5, doses: 0.8 mg/kg for siRNA targeting CDS and 0.4 mg/kg for siRNA
targeting 39UTR) and FVII protein in the serum quantified by chromogenic assay. (E) Activity of siRNAs targeting CDS and 39UTR in the absence of
Ago1, 3, or 4. Legend in the bottom left corner of the graph also indicates the line in the X-axis describing the treatment type by gene (mean 6 s.d.,
n = 3). Mice knockout for different individual Argonaute genes and C57BL/6 control animals were i.v.-injected with one of two combinations of LNP-
formulated siRNAs targeting Fads1 and Rab5c (CDS-targeting for one gene, at 0.8 mg/kg and 39UTR-targeting for the other gene, at 0.4 mg/kg) or
with control Luciferase siRNA at 1.2 mg/kg.
doi:10.1371/journal.pone.0101749.g003
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measured the effects of siRNAs targeting CDS and 39UTR on the
mRNA and on the protein levels of coagulation factor VII (FVII)
following 24 hours long knockdown. The pattern of FVII protein
expression observed matched its mRNA expression pattern
(Fig. 3D), suggesting that the main effect of siRNA in the RISC
containing non-Slicer Argonautes is achieved through mRNA
destabilization and degradation, rather than inhibition of transla-
tion.
For all three genes tested: Fads1, Rab5c, and FVII (Figure 3B, C
and D, respectively) siRNAs targeting CDS had no effect on
mRNA levels in Ago22/2 mice, while 39UTR-targeted knock-
down in vivo was attenuated, but not abolished in the absence of
Ago2. Thus, the same Ago22/2 phenotype was observed in vivo as
in vitro: complete loss of CDS-targeted knockdown, at the protein
level, in addition to the mRNA level; partial loss of 39UTR-
targeted knockdown.
Having determined the effects of absence of Ago2 on siRNA
function in vivo, and considering the potential role of non-Slicer
Argonautes in the residual knockdown, we wanted to see if
deletion of any of them will impact 39UTR-targeted knockdown.
The absence of Argonaute 1 (the most abundant of non-Slicer
Argonaute proteins, see Table S2) in MEF cells had no effect on
siRNA activity, irrespective of its’ targeting within the transcript
(data not shown). For both genes tested in vivo, no difference in the
efficacy of knockdown (no changes in Fads1 or Rab5c mRNA
recovery) with siRNAs targeting either CDS or 39UTR was seen in
the absence of Ago1, 3, or 4 (Fig. 3E). As suggested previously [14]
the presence of Ago2 and its more robust Slicer-dependent activity
masked the effects, if any, of non-Slicer Argonaute proteins. It has
been shown previously, that overexpression of non-Slicer Argo-
naute proteins leads to shRNA inhibition [13], conceivably due to
competition for shRNA (which they can all bind [11,12,16]) with
the more effective Ago2 and/or due to competition for target site
binding between Ago2 and non-Slicer Argonaute containing
RISC complexes. Similar absence of effect of transient depletion of
non-Slicer Argonautes on knockdown had been shown previously
in cell culture [12,14].
Roles of individual non-Slicer Argonautes in siRNA-
directed knockdown
As shown in Figure 1D, we have reproduced Ago22/2
phenotype by siRNA-induced knockdown of Ago2 in vitro. Ability
to do the same in animals with individual non-Slicer Argonautes’
knockouts, would allow us to test the hypothesis that one particular
Argonaute protein is responsible for the observed residual activity
of siRNAs targeting 39UTR in the absence of Ago2, as has been
suggested for Ago1 [14], and to determine the potential roles of
non-Slicer Argonautes at physiological concentrations in vivo. We
have selected siRNA-induced knockdown as means for depletion,
as has been successfully done previously [12,14] despite the
predicted danger of undesired or unknown interference effects
[37], which we were careful to minimize by utilizing the lowest
effective dose, to avoid saturation of the RNAi pathway [13,38].
Persistent Knockdown of Ago2 mRNA by siRNA
in vivo. First, we confirmed ability of Ago2 siRNA to down-
regulate targeted mRNA level in vivo (Fig. 4A). Single treatment of
mice with 0.5 mg/kg dose of 39UTR-targting siRNA led to 70%
reduction in Ago2 mRNA level, and practically no Ago2 mRNA
restoration was observed for 7 days (Fig. 4A). Since our delivery
system mainly targets hepatocytes [39,40], non-parenchymal liver
cells may contribute to the residual Ago2 signal detected in total
liver samples. Persistence of knockdown may be due to the activity
of non-Slicer Argonautes, rather than to the activity of a fraction of
Ago2 protein remaining in hepatocytes still bound to siRNA
targeting Ago2 mRNA, as the siRNA used to diminish its
expression targets 39UTR of Ago2 mRNA. We have seen
comparable depth of knockdown with siRNAs targeting 39UTRs
of other genes’ mRNAs in Ago22/2 MEF cells (Fig. 1A) and mice
(Fig. 3C). It has been shown previously, that Ago2 protein has a
relatively long half-life, on the order of days [41,42]. Since Ago2
mRNA knockdown was persistent, in subsequent experiments we
postponed the second injection (with target-gene siRNA, e.g.
Fads1) several days in order to reach minimum protein level.
Ago2 knockdown reproduces Ago22/2 phenotype
in vivo. Pretreatment of wild-type C57BL/6 mice with Ago2
siRNA four days before the injection of siRNA targeting CDS of
FVII mRNA led to complete loss of this duplex activity, while co-
injected siRNA targeting 39UTR of Rab5c mRNA remained active
(Fig. 4B). Thus, as we have shown earlier in vitro (Fig. 1D), Ago2
KD with siRNA reproduces Ago2 KO phenotype in vivo: it leads to
complete loss of CDS-targeted knockdown, and to partial loss of
39UTR-targeted knockdown. This allows/justifies utilization of
Ago2 knockdown in mice knockout for non-Slicer Argonautes, to
determine their roles in the observed residual knockdown.
Since Ago1 is the most abundant of non-Slicer Argonautes, and
it has previously been shown to play the major role in Ago2-
independent silencing [14] we have started by measuring the
efficacy of Rab5c 39UTR-targeted knockdown in Ago12/2 mice
pre-treated with anti-Ago2 siRNA. No difference in the level of
knockdown was detected between wild-type and Ago12/2 mice
treated with Ago2 siRNA (data not shown). We surmise that
apparent absence of Ago1 role in siRNA knockdown in this case
may be due to some preexisting properties, compensating for the
lack of Ago1 in these animals.
One interesting potential application of Ago2 knockdown may
be for confirmation that the phenotype observed upon a gene’s
knockdown is not due to off-target effects [43], as they persist in its
absence [14].
Combined Knockdown of Ago1 and Ago2 Further
Decrease Rab5c mRNA Knockdown by siRNA targeting
39UTR. Next we tested the effect of knockdown of Ago1
together with Ago2 in wild-type mice on the activity of siRNA
targeting 39UTR of Rab5c mRNA introduced four days later. We
have previously seen no difference in knockdown between wild-
type and Ago12/2 mice (Fig. 3E), here, after Ago1 knockdown
alone in wild-type mice, Rab5c knockdown result was also the same
as in Luciferase siRNA pretreated mice (data not shown).
Depletion of Ago1 in addition to Ago2 (unlike depletion of Ago2
in Ago12/2 animals, see above) further decreased the depth of
Rab5c knockdown (Fig. 4C), indicating Ago1 role in Slicer-
independent siRNA-directed mRNA degradation. At the same
time, strong residual activity of Rab5c 39UTR siRNA suggested
that the remaining two Argonautes are also functionally interact-
ing with 39UTR-targeting siRNAs. It has been reported that all
miRNA species were still similarly processed and loaded onto
Ago3 in Ago1/2 double knockout skin samples, suggesting that
Ago3 is equally competent in the processing and loading of
miRNAs as Ago1 and Ago2 and that the passenger strand cleavage
activity of Ago1 and Ago2 is dispensable for the biogenesis of
hundreds of miRNAs in the skin [44]. We also see Ago3 play a role
in siRNA-targeted mRNA knockdown in mouse liver.
Ago1 and Ago3 appear to be redundant in 39UTR-directed
siRNA knockdown. To confirm the role of Ago3, combination
of Ago1+2 knockdown with Ago3 or Ago4 knockout was used.
The results obtained for Fads1 mRNA knockdown by siRNA
targeting 39UTR in vivo support Argonautes’ redundancy, in
particular the role of Ago3 in 39UTR-targeted siRNA-directed
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knockdown (Fig. 4D). Minimal effect of Ago4 knockout may be
due to its very low expression in liver (Table S2).
A clear trend towards Fads1 mRNA level recovery in Ago32/2
animals further supports the involvement of Ago3 in siRNA-
mediated 39UTR-targeted knockdown. Deep residual knockdown
of Fads1 mRNA in the absence of three out of four Argonautes is
probably due to incomplete loss of Ago1 and Ago2.
Taken together, our results lead to the following conclusions: (i)
for knockdown directed by exogenous siRNA in vivo, miRNA-like
mechanism may work in addition to Ago2 cleavage; (ii) non-Slicer
Argonautes (Ago1 and Ago 3) are instrumental to the observed
miRNA-like mechanism of knockdown, and (iii) they are
redundant in this role in mouse liver. These conclusions provide
two suggestions for future improvement of RNAi application
strategy. First, it may be beneficial to target 39UTR, rather than
CDS, to turn non-Slicer Argonautes from siRNA deposit/
sequestration platforms [13] into active participants of knockdown
[14,24]. Second, it may be useful to take into account the stability
and persistence of loaded RISC complexes [8,42,45], in particular
in quiescent cells [46], when frequency and dosage of siRNA
treatment are selected [47–49].
Materials and Methods
siRNA design, synthesis, selection, and formulation
We selected the candidate 21-mer siRNAs with maximum
target transcript specificity as described [49]. Mouse mRNA
sequences (listed in Table S1) were used to select appropriate
candidate target sequences for their corresponding siRNAs.
Single-stranded chemically modified RNAs were synthesized at
Alnylam Pharmaceuticals (Cambridge, MA) using standard
phosphoramidite chemistry. Deprotection and purification of the
crude oligoribonucleotides by anion exchange HPLC were carried
out according to established procedures. siRNA duplexes were
generated by annealing equimolar amounts of complementary
sense and antisense strands. All siRNAs used in this study are listed
in Table S1.
Figure 4. Effect of individual Argonautes in vivo. (A) C57BL/6 mice were i.v.-injected with LNP-formulated siRNA targeting Ago2–39UTR or with
control Luciferase siRNA at 0.5 mg/kg. Animals were sacrificed at indicated time points and Ago2 mRNA was quantified by bDNA assay (mean 6 s.d.,
n = 5). (B) bDNA measurement of mRNA knockdown of Rab5c (by siRNA targeting 39UTR-near at 0.5 mg/kg) and FVII (by siRNA targeting CDS at
0.2 mg/kg) in wild-type mice (mean 6 s.d., n = 4–5) following 4 days of Ago2 knockdown (by siRNA targeting 39UTR at 0.5 mg/kg). (C) Animals were
i.v.-injected with Ago1, Ago2, or Luc siRNA on day 1, Ago1 treated animals were further i.v.-injected with Ago2 on day 2; and Rab5c-39UTR-near siRNA
was introduced on day 5 (where indicated; each siRNA was dosed at 0.5 mg/kg). All animals were sacrificed on day 6. Liver mRNA levels for Ago1,
Ago2, and Rab5c were measured by bDNA assay (mean6 s.d., n = 4–5). (D) Mice were i.v.-injected with LNP containing 0.5 mg/kg siRNA against each
of Ago1 and Ago2 (or 1 mg/kg of Luciferase control siRNA) twice at week long intervals, at the end of the second week mice were i.v.-injected with
Fads1–39UTR or Luciferase control siRNAs at 0.4 mg/kg. Mice were sacrificed for liver RNA extraction the day after the last injection (mean 6 s.d.,
n = 3).
doi:10.1371/journal.pone.0101749.g004
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FVII-CDS- and luciferase-specific control siRNAs were de-
scribed earlier [50]. siRNAs specific to murine Ago1, Ago2, FVII-
39UTR, Fads1, and Rab5c mRNAs were identified by screening
sets of 20–30 siRNA duplexes per gene. Best duplexes were
selected by transfection of NIH/3T3 cells and IC50 values
determined. siRNA specific to FVII-39UTR were identified
similarly, except cultured primary mouse hepatocytes were used
for screening. Duplexes selected for each target were synthesized
on a larger scale at Alnylam Pharmaceuticals (Cambridge, MA)
and were characterized by electrospray mass spectrometry and
anion exchange HPLC prior to their use in LNP preparation,
which was performed as described [40,51].
In vitro studies
Derivation and manipulation of mouse embryonic fibroblast
(MEF) cell lines with individual Argonaute genes’ deletions were
described previously [31]. MEF cells were maintained in
Dulbecco’s modified Eagle’s medium (Life Technologies) supple-
mented with Non-Essential Amino Acids, Penicillin, Streptomycin,
and 15% fetal bovine serum. For transfection Lipofectamine
RNAiMAX (Life Technologies) was used following manufacturer’s
protocol for reverse transfection, MEF cells were plated at average
density of 100000 cells/cm2; siRNA concentrations are indicated
in the text. Target genes’ mRNA knockdown following transfec-
tions was analyzed by branched DNA assay as described [52] or
by quantitative reverse transcription real-time PCR (qRT-PCR)
measurement of target genes’ mRNA levels using TaqMan gene-
specific probes (Applied Biosystems) on a LightCycler 480 II
(Roche). GAPDH mRNA levels were used for data normalization.
The probes used in the bDNA assay were QuantiGene 2.0 RNA
Probe Sets for mouse FVII, Fads1, Fads2, Rab5a, Rab5c, and Gapdh
mRNAs (Affymetrix).
For rescue experiment pMigR vectors bearing wild-type or
D669A mouse Ago2 coding sequences [31] were transfected with
Fugene HD into Ago22/2 MEF cells, followed by reverse
transfection with siRNA the next day.
Rab5c 59RACE was done with GeneRacer kit (Life Technolo-
gies), essentially as described previously [49], on 2 mg of the total
RNA isolated from Ago2fl/fl MEF cells and Ago22/2 MEF cells
transfected with 10 nM Rab5c 39UTR-near or Luciferase control
siRNA, avoiding dephosphorylation and decapping steps. Gene
specific primers used for 59RACE were: Rab5c-GSPrev-1198 (for
first round of PCR) 59-GCAAGAAGGGAAGAAAGGGT-
GACT-39 and Rab5c-GSPrev-1020 (for Nested PCR) 59-ACA-
GAAAGGTGCAGGTGGAATAACTC-39. ‘‘A Plasmid Editor’’
program by M. Wayne Davis (http://biologylabs.utah.edu/
jorgensen/wayned/ape/) was used for primer design and
sequence alignment.
Animal studies
All experiments done in wild-type animals were conducted at
Alnylam Pharmaceuticals and strictly followed institutional,
federal, state and local guidelines and were approved by
Institutional Animal Care and Use Committee (AAALAC Unit
Number 001345, NIH assurance number A4517-01). All the
animals were kept in a conventional barrier animal facility with a
climate-controlled environment having 12-hour light/dark cycles
in polystyrene cages containing wood shavings, fed standard
rodent chow and water.
For the experiments, female 8 weeks old C57BL/6 mice were
purchased from Charles River Laboratories. For silencing
experiments mice were i.v. bolus injected (10 mL/g; maximum
total amount of siRNA delivered per injection was 1.2 mg/kg and
in each experiment all animals received the same total dose) and
sacrificed by CO2 overdose before tissue harvest. Chromogenic
assay for quantification of Factor VII protein in mouse serum and
bDNA assay for measurement of mRNA in mouse liver have been
done as recently described [52]. The probes used in the bDNA
assay are listed above.
All experiments done in knockout animals were conducted at
Rockefeller University. Mice were housed under specific patho-
gen-free conditions and experimental protocols were approved by
the Rockefeller University Institutional Animal Care and Use
Committee. Individual Argonautes’ floxed models were described
previously [31]. In the case of Ago2 the mice with a floxed gene
were bred to Alb-Cre (obtained from Jackson Labs) for the
hepatocyte conditional deletion. All mice were bred onto a
C57BL/6 background. In vivo experiments in knockout animals
were carried out in a blinded fashion. Total RNA was isolated
from snap-frozen, ground liver samples with RNeasy 96 Universal
Tissue kit (Qiagen) as described by the manufacturer, reverse
transcribed with High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) and used for qRT-PCR measurement of
target genes’ mRNA levels using TaqMan gene-specific probes
(Applied Biosystems) on a LightCycler 480 II (Roche). GAPDH
mRNA levels were used for data normalization.
Western blot analysis
For western blot analysis whole liver lysates were prepared from
liver powders from control, siRNA-treated, and knockout animals,
30 mg of total protein (measured by BCA assay) run on SDS-
PAGE, transferred to nitrocellulose membranes and incubated
with antibodies to Ago2 RN029PW (MBL Ribonomics). beta-
Actin levels (clone AC-15, Sigma-Aldrich cat.no.A1978) were used
to normalize for protein loading. Protein bands were visualized by
using LI-COR Odyssey infrared imaging system (with appropriate
secondary antibodies: goat anti-rabbit IgG IRDye 800CW and
goat anti-mouse IgG IRDye 680LT).
Supporting Information
Figure S1 Ago2 rescue experiment. MEF Ago22/2 cells
were transiently transfected with Ago2 wild-type or Ago2(D669A)
Slicer-incompetent mutant, followed after 24 hours by a
transfection with serial dilutions of Fads1-CDS or Fads1-39UTR
targeting siRNAs. (A) Fads1 (and Ago2) mRNA levels were
determined by qRT-PCR. Three independent transfections were
done in duplicate; averages of duplicates of each transfection are
shown. Western blot (B) and qRT-PCR (C) analyses of wild-type
and D669A mutant Ago2 expression levels.
(PPT)
Figure S2 Features of siRNA-mediated degradation of
mRNA in the absence of Ago2. (A) Deeper knockdown is
achieved by 24 h compared to 3 h in all Rab5c siRNA treated
cells, except MEF Ago22/2 treated with CDS-targeting siRNA,
where no significant knockdown is detected at either time point.
Data is presented as mean 6 s.d. for two technical replicates of
bDNA measurement. (B) Complete image of the 59RACE Nested
PCR electrophoresis, shown in FIGURE 2B, includes two
different control reactions for each cell type.
(PPT)
Figure S3 59RACE products’ sequences alignment.
Sequenced cloned PCR products were aligned to mouse Rab5c
mRNA NM_024456.3 (by APE software). mRNA sequence
complementary to Rab5c-39UTR-near siRNA is highlighted
green (cleavage site marked with an asterisk).
(PPT)
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Table S1 Sequences and relative target-site positions of
siRNAs.
(XLS)
Table S2 Relative Argonaute mRNA abundance.
(XLS)
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